Imidazole

Imidazole

SCHEMBL703024

O=P(O)(O)OCC(O)CO.c1c[nH]cn1

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.39
FKBP5 Q13451 1/20 0.39
PGK1 P00558 1/20 0.35
PGK2 P07205 1/20 0.35
LPAR1 Q92633 7/20 0.35
LPAR5 Q9H1C0 2/20 0.35
LPAR6 P43657 1/20 0.35
LPAR4 Q99677 1/20 0.35
LPAR2 Q9HBW0 1/20 0.35
LPAR3 Q9UBY5 1/20 0.35
ENPP2 Q13822 1/20 0.35
PGD P52209 3/20 0.33
MPI P34949 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glycerin SCHEMBL1535282 0.84 ALDH1A1 (0.48) ALDH1A1FKBP5
Glycerin SCHEMBL23579100 0.78 ALDH1A1 (0.59) ALDH1A1FKBP5
Glycerin SCHEMBL231119 0.78 ALDH1A1 (0.59) ALDH1A1FKBP5
Glycerin SCHEMBL23579221 0.78 ALDH1A1 (0.59) ALDH1A1FKBP5
SCHEMBL213379 0.78 PGK1 (0.52) ALDH1A1PGK1PGK2LPAR1LPAR5
SCHEMBL6655023 0.78 PGK1 (0.52) ALDH1A1PGK1PGK2LPAR1LPAR5
SCHEMBL7340 0.78 PGK1 (0.52) ALDH1A1PGK1PGK2LPAR1LPAR5
SCHEMBL14278848 0.78 PGK1 (0.52) ALDH1A1PGK1PGK2LPAR1LPAR5
SCHEMBL14278847 0.78 PGK1 (0.52) ALDH1A1PGK1PGK2LPAR1LPAR5
SCHEMBL7341 0.78 PGK1 (0.52) ALDH1A1PGK1PGK2LPAR1LPAR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119220476-B Recombinant escherichia coli construction and application for improving yield of difucosyl lactose 天津合生领航生物科技有限公司 2025-02-28 CN claimed
US-20240124907-A1 Engineered Biosynthetic Pathways for Production of Histamine by Fermentation ZYMERGEN INC. (US) 2024-04-18 US claimed
US-11739355-B2 Engineered biosynthetic pathways for production of histamine by fermentation ZYMERGEN INC. (US) 2023-08-29 US claimed
US-20060034817-A1 Cloning, overexpression and therapeutic use of bioactive histidine ammonia lyase UNIVERSITY OF SOUTH CAROLINA 2006-02-16 US claimed
EP-0688210-B1 USE OF CARNOSINE IN COMBINATION WITH UROCANIC ACID FOR TREATMENT OF PHOTODERMATOSES BEIERSDORF AG (DE) 2004-02-25 EP claimed
US-5723482-A CARNOSINE OR DERIVATIVE, UROCANIC ACID OR DERIVATIVE BEIERSDORF AG (DE) 1998-03-03 US claimed
EP-0813602-A1 HERBICIDE RESISTANT PLANTS Ciba-Geigy Japan Limited (JP) 1997-12-29 EP claimed
US-5541310-A DNA ENCODING IMIDAZOLEGLYCEROL PHOSPHATE DEHYDRATASE CIBA-GEIGY CORPORATION (US) 1996-07-30 US claimed
EP-0688210-A1 USE OF CARNOSINE OR A COMBINATION WITH UROCANIC ACID FOR TREATMENT OF PHOTODERMATOSES Beiersdorf Aktiengesellschaft (DE) 1995-12-27 EP claimed
WO-1994026909-A1 HERBICIDE RESISTANT PLANTS JAPAT LTD. (CH) 1994-11-24 WO claimed
WO-1994021245-A1 USE OF CARNOSINE OR A COMBINATION WITH UROCANIC ACID FOR TREATMENT OF PHOTODERMATOSES BEIERSDORF AG (DE) 1994-09-29 WO claimed
US-20260125432-A1 MALTOSE DEPENDENT DEGRONS, MALTOSE-RESPONSIVE PROMOTERS, STABILIZATION CONSTRUCTS, AND THEIR USE IN PRODUCTION OF NON-CATABOLIC COMPOUNDS AMYRIS INC (US) 2026-05-07 US disclosed
US-12516090-B2 Maltose dependent degrons, maltose-responsive promoters, stabilization constructs, and their use in production of non-catabolic compounds Amyris, Inc. (US) 2026-01-06 US disclosed
US-20250352486-A1 NANOPARTICLES FOR USE IN THE TREATMENT OF INFECTIONS CAUSED BY BIOFILMS UNIVERSITAT POLITÈCNICA DE VALÈNCIA (ES) 2025-11-20 US disclosed
EP-4647496-A1 NOVEL PROMOTER AND USE THEREOF CJ CheilJedang Corporation (KR) 2025-11-12 EP disclosed
WO-1995014385-A1 TRIAZOLE PHOSPHONATE PESTICIDES AGREVO UK LIMITED (GB) 1995-06-01 WO disclosed
WO-1995011969-A1 METHODS FOR SCREENING FOR ANTIMYCOTICS RIBOGENE, INC. (US) 1995-05-04 WO disclosed
WO-1994026909-A1 HERBICIDE RESISTANT PLANTS JAPAT LTD. (CH) 1994-11-24 WO disclosed
WO-1994021245-A1 USE OF CARNOSINE OR A COMBINATION WITH UROCANIC ACID FOR TREATMENT OF PHOTODERMATOSES BEIERSDORF AG (DE) 1994-09-29 WO disclosed
EP-0054223-A2 Plasmid vectors for eukaryotic cells and method for selecting transfected eukaryotic cells F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1982-06-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125432-A1 MALTOSE DEPENDENT DEGRONS, MALTOSE-RESPONSIVE PROMOTERS, STABILIZATION CONSTRUCTS, AND THEIR USE IN PRODUCTION OF NON-CATABOLIC COMPOUNDS MAX, JUND, MYCBP ALDH1A1 4768/4885FKBP5 653/4885PGK1 1371/4885
US-20060034817-A1 Cloning, overexpression and therapeutic use of bioactive histidine ammonia lyase HEXB, AHCYL1, HRH1 ALDH1A1 1530/4885FKBP5 2688/4885PGK1 1071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.